UTMD Q1 Revenue Plunges 10.2%, EPS Down 11% on Lost Distributor Sales
UTMD sits 36% above its 52-week low of $51.26.
Summary
Utah Medical Products, Inc. reported a significant decline in its first-quarter 2026 financial performance, with revenues down 10.2%, net income falling 14.4%, and EPS decreasing 11.0% compared to the prior year. These declines were primarily driven by the loss of sales to a major China distributor and an OEM customer, which collectively accounted for a substantial portion of the revenue reduction. While the company stated these results were consistent with previously announced projections, the double-digit drops in key financial metrics are material and confirm ongoing operational challenges. Traders will be watching for signs of sales stabilization or new growth drivers in subsequent quarters to offset the impact of lost business.
At the time of this announcement, UTMD was trading at $69.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $221.8M. The 52-week trading range was $51.26 to $71.81. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Access Newswire.